335 related articles for article (PubMed ID: 33113496)
1. Conquering CRISPR: how phages overcome bacterial adaptive immunity.
Malone LM; Birkholz N; Fineran PC
Curr Opin Biotechnol; 2021 Apr; 68():30-36. PubMed ID: 33113496
[TBL] [Abstract][Full Text] [Related]
2. Covalent Modifications of the Bacteriophage Genome Confer a Degree of Resistance to Bacterial CRISPR Systems.
Liu Y; Dai L; Dong J; Chen C; Zhu J; Rao VB; Tao P
J Virol; 2020 Nov; 94(23):. PubMed ID: 32938767
[TBL] [Abstract][Full Text] [Related]
3. Resistance is not futile: bacterial 'innate' and CRISPR-Cas 'adaptive' immune systems.
Fineran PC
Microbiology (Reading); 2019 Aug; 165(8):834-841. PubMed ID: 30958259
[TBL] [Abstract][Full Text] [Related]
4. Exploitation of the Cooperative Behaviors of Anti-CRISPR Phages.
Chevallereau A; Meaden S; Fradet O; Landsberger M; Maestri A; Biswas A; Gandon S; van Houte S; Westra ER
Cell Host Microbe; 2020 Feb; 27(2):189-198.e6. PubMed ID: 31901522
[TBL] [Abstract][Full Text] [Related]
5. A jumbo phage that forms a nucleus-like structure evades CRISPR-Cas DNA targeting but is vulnerable to type III RNA-based immunity.
Malone LM; Warring SL; Jackson SA; Warnecke C; Gardner PP; Gumy LF; Fineran PC
Nat Microbiol; 2020 Jan; 5(1):48-55. PubMed ID: 31819217
[TBL] [Abstract][Full Text] [Related]
6. How bacteria control the CRISPR-Cas arsenal.
Leon LM; Mendoza SD; Bondy-Denomy J
Curr Opin Microbiol; 2018 Apr; 42():87-95. PubMed ID: 29169146
[TBL] [Abstract][Full Text] [Related]
7. The Discovery, Mechanisms, and Evolutionary Impact of Anti-CRISPRs.
Borges AL; Davidson AR; Bondy-Denomy J
Annu Rev Virol; 2017 Sep; 4(1):37-59. PubMed ID: 28749735
[TBL] [Abstract][Full Text] [Related]
8. Delivery of CRISPR-Cas systems using phage-based vectors.
Fage C; Lemire N; Moineau S
Curr Opin Biotechnol; 2021 Apr; 68():174-180. PubMed ID: 33360715
[TBL] [Abstract][Full Text] [Related]
9. Cost and benefits of clustered regularly interspaced short palindromic repeats spacer acquisition.
Bradde S; Mora T; Walczak AM
Philos Trans R Soc Lond B Biol Sci; 2019 May; 374(1772):20180095. PubMed ID: 30905281
[TBL] [Abstract][Full Text] [Related]
10. Multiple mechanisms for CRISPR-Cas inhibition by anti-CRISPR proteins.
Bondy-Denomy J; Garcia B; Strum S; Du M; Rollins MF; Hidalgo-Reyes Y; Wiedenheft B; Maxwell KL; Davidson AR
Nature; 2015 Oct; 526(7571):136-9. PubMed ID: 26416740
[TBL] [Abstract][Full Text] [Related]
11. Variability in the durability of CRISPR-Cas immunity.
Chabas H; Nicot A; Meaden S; Westra ER; Tremblay DM; Pradier L; Lion S; Moineau S; Gandon S
Philos Trans R Soc Lond B Biol Sci; 2019 May; 374(1772):20180097. PubMed ID: 30905283
[TBL] [Abstract][Full Text] [Related]
12. Deciphering and shaping bacterial diversity through CRISPR.
Briner AE; Barrangou R
Curr Opin Microbiol; 2016 Jun; 31():101-108. PubMed ID: 27045713
[TBL] [Abstract][Full Text] [Related]
13. The Biology of CRISPR-Cas: Backward and Forward.
Hille F; Richter H; Wong SP; Bratovič M; Ressel S; Charpentier E
Cell; 2018 Mar; 172(6):1239-1259. PubMed ID: 29522745
[TBL] [Abstract][Full Text] [Related]
14. The Rcs stress response inversely controls surface and CRISPR-Cas adaptive immunity to discriminate plasmids and phages.
Smith LM; Jackson SA; Malone LM; Ussher JE; Gardner PP; Fineran PC
Nat Microbiol; 2021 Feb; 6(2):162-172. PubMed ID: 33398095
[TBL] [Abstract][Full Text] [Related]
15. Impact of Different Target Sequences on Type III CRISPR-Cas Immunity.
Maniv I; Jiang W; Bikard D; Marraffini LA
J Bacteriol; 2016 Jan; 198(6):941-50. PubMed ID: 26755632
[TBL] [Abstract][Full Text] [Related]
16. Keeping crispr in check: diverse mechanisms of phage-encoded anti-crisprs.
Trasanidou D; Gerós AS; Mohanraju P; Nieuwenweg AC; Nobrega FL; Staals RHJ
FEMS Microbiol Lett; 2019 May; 366(9):. PubMed ID: 31077304
[TBL] [Abstract][Full Text] [Related]
17. Conditional tolerance of temperate phages via transcription-dependent CRISPR-Cas targeting.
Goldberg GW; Jiang W; Bikard D; Marraffini LA
Nature; 2014 Oct; 514(7524):633-7. PubMed ID: 25174707
[TBL] [Abstract][Full Text] [Related]
18. Specialized Weaponry: How a Type III-A CRISPR-Cas System Excels at Combating Phages.
Niewoehner O; Jinek M
Cell Host Microbe; 2017 Sep; 22(3):258-259. PubMed ID: 28910631
[TBL] [Abstract][Full Text] [Related]
19. Cas13-induced cellular dormancy prevents the rise of CRISPR-resistant bacteriophage.
Meeske AJ; Nakandakari-Higa S; Marraffini LA
Nature; 2019 Jun; 570(7760):241-245. PubMed ID: 31142834
[TBL] [Abstract][Full Text] [Related]
20. Bacterial alginate regulators and phage homologs repress CRISPR-Cas immunity.
Borges AL; Castro B; Govindarajan S; Solvik T; Escalante V; Bondy-Denomy J
Nat Microbiol; 2020 May; 5(5):679-687. PubMed ID: 32203410
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
